Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination This small study had amazing results. Compared to matched historical controls, median progression free survival was 25.3 months in the vaccine group vs. 8.0 months in the historical control group and median overall survival was 41.1 vs. 19.2 months. Only 1 patient had significant side effects, an allergic reaction to the immune stimulant they used - which was discontinued and she was able to continue on the vaccine.
Disclaimer: I (Al Musella, DPM) am on the patient advisory board at The Preston Robert Tisch Brain Tumor Center.
